SG/CALL/GILEAD SCIENCES/100/0.1/20.06.25

SG/CALL/GILEAD SCIENCES/100/0.1/20.06.25 Stock

DE000SU26EX4

Market Closed - Boerse Frankfurt Warrants 03:36:12 2024-07-05 pm EDT
0.065 ^EUR	+3.17%

Current month	-20.48%
1 month	+37.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart SG/CALL/GILEAD SCIENCES/100/0.1/20.06.25

Latest news about GILEAD SCIENCES, INC.

HIV Breakthrough - Drug Trial Shows Injection Twice a Year Is 100 Percent Effective Against Infection [analysis]	Jul. 03	AQ
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	Jul. 01	MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	Jul. 01	CI
Gilead Benefit Helps Employees Navigate Cancer Care	Jul. 01	AQ

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.066	+4.76%
24-07-04	0.063	-5.97%
24-07-03	0.067	-19.28%
24-07-02	0.083	-4.60%
24-07-01	0.087	+4.82%

Real-time Boerse Frankfurt Warrants

Last update July 05, 2024 at 03:36 pm EDT

More quotes

Static data

Product type	Warrant Plain-Vanilla
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Société Générale
WKN	SU26EX
ISIN	DE000SU26EX4
Date issued	2023-12-05
Strike	100 $
Maturity	2025-06-20 (350 Days)
Parity	10 : 1
Emission price	0.28 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	0.61 €
Lowest since issue	0.039 €
Spread	0.01 €
Spread %	13.70%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company